- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Real-World Analysis: Secukinumab Improves Psoriatic Arthritis Outcomes at 6 Months
Just like in clinical trials, a real-world analysis of patients with psoriatic arthritis who were treated with secukinumab achieved minimal disease activity, as well as other improvements.
Just like in clinical trials, a real-world analysis of patients with psoriatic arthritis (PsA) who were treated with secukinumab achieved minimal disease activity (MDA), as well as other improvements, according to an abstract presented at the European League Against Rheumatism’s annual meeting.
The researchers analyzed 100 patients with PsA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry who initiated and maintained secukinumab for 6 months. The patients had initiated the treatment after April 1, 2017, and had a follow-up visit in the 6 months after treatment initiation.
The primary outcome was MDA, which was defined as meeting 5 criteria out of 7 total: tender joint count (TJC) ≤1; swollen joint count (SJC) ≤1; psoriasis affected body surface area (BSA) <3%; patient assessment of pain on visual analog scale (VAS) ≤15; patient global assessment VAS ≤20; Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ 0.5; and tender entheseal points ≤ 1 using the Leeds Enthesitis Index (LEI).
The mean age of patients was 51.6 years and the mean symptom and disease duration were 10.8 and 7.0 years, respectively. Thirty percent of patients initiated secukinumab at the 150 mg dose and the remaining 70% initiated it at 300 mg. Only 17 of the patients were initiating secukinumab as their first biologic—34 patients started it as their second biologic, 26 as their third, and 23 as their fourth or greater.
At the time of initiation, 75 of 90 patients were not in MDA and 36.6% of those with follow-up data had achieved MDA at 6 months. In addition, 28 patients (41.2%) with TJC ≥1, 24 patients (44.4%) with SJC ≥1, and 17 patients (60.7%) with enthesitis achieved resolution at 6 months.
According to the researchers, at 6 months, there were improvements in clinical outcomes and patient-reported outcomes (PROs) not only in the overall population, but also in patients who were initiating the treatment as a fourth-line or greater biologic.
“Consistent with clinical trials, real-world patients treated with secukinumab achieved MDA as well as improvement in clinical manifestations, PROs, and work productivity,” the authors concluded.
Reference
Mease PJ, Blachley T, Glynn M, et al. Secukinumab improves clinical and patient-reported outcomes at 6 months among patients with psoriatic arthritis in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Presented at: EULAR 2020; June 3-6, 2020; Abstract SAT0429. https://ard.bmj.com/content/79/Suppl_1/1169.1
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
